| Quarter | Score |
|---|---|
| 2023-Q3 | 50.1 |
| 2023-Q4 | 65.6 |
| 2024-Q1 | 49.7 |
| 2024-Q2 | 51.6 |
| 2024-Q3 | 79.4 |
| 2024-Q4 | 80.4 |
| 2025-Q1 | 71.6 |
| 2025-Q2 | 69.5 |
| 2025-Q3 | 69.9 |
| 2025-Q4 | 68.8 |
| 2026-Q1 | 70.9 |
| 2026-Q2 | 66.9 |
Funds reducing exposure or consensus momentum fading
Trading +114.6% above funds' purchase price — elevated pullback risk
2 of 16 tracked funds hold LLYVA. Avg conviction: 0.8%. Net trimming. First tracked at $43.51 (current +114.6% vs tracked).
ValueAct Capital has 1.4% in this stock
Prices are approximate, based on 13F reported values (position value / shares), not actual cost basis. Data covers 16 tracked value-oriented funds. Holdings are reported quarterly with a ~45-day lag. Stock splits may affect share count comparisons. Returns are not annualized.
| Fund | % of Portfolio | Action |
|---|---|---|
| ValueAct Capital | 1.4% | Reduce |
| Berkshire Hathaway | 0.2% | Hold |